male scientists in protective covering using a microscope

Large Molecules

<a href="https://www.bioagilytix.com/blog/category/industry-update/">Industry Update</a>

The Benefits of Hiring the Right CRO

  • January 27, 2021

Short for Contract Research Organization, a CRO is a company that provides clinical research support to the pharmaceutical, biotech and medical industries on a contract…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cell-based-assays/">Cell-Based Assays</a>

The Importance of Cytokine Detection and Analysis

  • December 2, 2020

Cytokines are a broad class of soluble proteins, glycoproteins, and peptides that act as chemical messengers of the immune system. These small proteins are essential…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

CLIA, COLA & CAP: What’s the Difference?

  • August 19, 2020

BioAgilytix’s CLIA Laboratory Director, Natalie Smith, outlines the differences between CLIA, CAP & COLA regulations & accreditations, and what they mean for laboratory testing quality.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Answering Your Questions on Developing a Relative Potency Assay for an Anti-Influenza mAb

  • May 22, 2020

Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

New Research on the Diagnostic Journey of Patients with Ankylosing Spondylitis

  • May 1, 2020

BioAgilytix's Regan Reynolds shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cro-selection/">CRO Selection</a>

Turning Around a Troubled Study: A Rescue Project Success Story

  • April 13, 2020

When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices

  • January 2, 2020

BioAgilytix has been fortunate enough to have several of our team members participate as co-authors on all three AAPS white papers in the series on…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/uncategorized/">Uncategorized</a>

Bioanalytical Testing Under GMP: Optimizing Cell-Based Potency Assays

  • December 4, 2019

Cell-based bioassays are expected by health agencies as one of the release specification methods for potency assessments in the drug development process. We take a…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cro-selection/">CRO Selection</a>

To the Rescue: Applying a Novel Approach to Minimize False Positive ADA Assay Results

  • July 2, 2019

Target interference can cause false positive ADA assay results and stall out promising drugs. This could have been the case for one study involving an…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioanalytical-platforms/">Bioanalytical Platforms</a>

Ligand-Binding Assay Optimization, Part 1: Critical Attributes of Platforms Used

  • January 8, 2019

Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the…

Find Out More